BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 6341756)

  • 1. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antihypertensive therapy with guanfacine. A multicenter trial with Estulic Wander 1 mg].
    Schäfer N; Knaup G
    MMW Munch Med Wochenschr; 1982 Mar; 124(10):249-52. PubMed ID: 6806612
    [No Abstract]   [Full Text] [Related]  

  • 3. Examination of the antihypertensive action of long-term estulic (Egis-Sandoz) treatment.
    Zeher M; Antal L; Azad AQ; Szegedi G
    Ther Hung; 1988; 36(3):103-8. PubMed ID: 3074520
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG; Bloxham CA; Walker JM
    Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guanfacine for hypertension.
    Med Lett Drugs Ther; 1987 May; 29(740):49-50. PubMed ID: 2883560
    [No Abstract]   [Full Text] [Related]  

  • 7. [Guanfacine (Estulic) in the monotherapy of essential hypertension, grades I and II, according to WHO].
    Mayer K; Lupínek Z; Janousek S; Podrouzková B
    Cas Lek Cesk; 1984 Oct; 123(43):1306-11. PubMed ID: 6391673
    [No Abstract]   [Full Text] [Related]  

  • 8. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical experience with guanfacine.
    Fetkovská N; Brimichová G; Sebeková K; Dzúrik R
    Cor Vasa; 1987; 29(4 Suppl 1):23-9. PubMed ID: 3315447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 12. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Controlled doubleblind study on dose-effect relationship of guanfacine a long-acting hypotensive guanidine derivative (author's transl)].
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G
    Arzneimittelforschung; 1980; 30(6):1005-7. PubMed ID: 6998487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guanfacine in primary arterial hypertension: a long-term open clinical study].
    Román O; Valenzuela MA; Salazar R
    Rev Med Chil; 1982 Dec; 110(12):1179-84. PubMed ID: 6764015
    [No Abstract]   [Full Text] [Related]  

  • 15. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ; Laszt A; Paran E; Ben Ari J; Goren Y; Modan M
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract]   [Full Text] [Related]  

  • 16. [Minimal useful dose of guanfacine in patients with essential hypertension].
    Pérez Olea J; Ortíz N; Soledad Bertoló M; Allel L; Goity C; Quevedo M
    Rev Med Chil; 1985 May; 113(5):420-4. PubMed ID: 3912882
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term efficacy and tolerance of the antihypertensive agent guanfacine.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):170-4. PubMed ID: 6370876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new centrally action antihypertensive agent guanfacine (BS 100-141).
    Dubach UC; Huwyler R; Radielovic P; Singeisen M
    Arzneimittelforschung; 1977; 27(3):674-6. PubMed ID: 326262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus.
    Dvorák I; Podrouzková B; Kocourková J; Kubesová H; Spác J; Nĕmcová H; Blaha M
    Cor Vasa; 1987; 29(4 Suppl 1):30-6. PubMed ID: 3315448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive therapy with guanfacine induces elevated plasma growth hormone levels in diabetic patients.
    Coves MJ; Gomis R; Casamitjana R; Lienas V; Vilaradell E
    J Med; 1989; 20(3-4):291-6. PubMed ID: 2572660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.